Herantis Pharma Oyj
HRPMF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $3 | $5 | $6 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1 | $0 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$5 | $0 | $0 |
| Operating Expenses | $5 | -$0 | $8 | $9 |
| Operating Income | -$5 | $0 | -$8 | -$9 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | -$1 | -$0 |
| Pre-Tax Income | -$5 | $0 | -$9 | -$13 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | $0 | -$9 | -$24 |
| % Margin | – | – | – | – |
| EPS | -0.24 | 0.016 | -0.64 | -2.2 |
| % Growth | -1,572.4% | 102.5% | 70.9% | – |
| EPS Diluted | -0.24 | 0.016 | -0.64 | -2.2 |
| Weighted Avg Shares Out | 20 | 17 | 15 | 10 |
| Weighted Avg Shares Out Dil | 20 | 17 | 15 | 10 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $1 | $1 | $0 |
| Depreciation & Amortization | $0 | -$0 | $16 | $16 |
| EBITDA | -$5 | $1 | $8 | $7 |
| % Margin | – | – | – | – |